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Abstract The expression of P-glycoprotein (P-gp) and canali-
cular multispecific organic anion transporter (cMOAT or Mrp2)
was evaluated by Western blotting analysis of rat tissues isolated
following daily administration (1 mg kg31 day31) of dexametha-
sone over 4 days. Dexamethasone rapidly increased P-gp
expression more than 4.5- and 2-fold in liver and lung,
respectively, while it was decreased 40% in kidney. cMOAT
expression was increased 2-fold in liver and kidney following
dexamethasone treatment. The levels of both proteins returned to
control values by 6 days after the conclusion of dexamethasone
administration. These results indicate that dexamethasone can
modulate P-gp and cMOAT expression in specific rat tissues and
may have significant relevance for patients treated with
dexamethasone as a single agent or in combination therapy with
other drugs.
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1. Introduction
Dexamethasone is a potent adrenal corticosteroid which has
anti-in£ammatory, immunosuppressant, anti-neoplastic and
anti-emetic properties. Dexamethasone has also been shown
to be transported by the P-glycoprotein from human adrenal
gland when expressed in porcine LLC-PK1 cells [1]. P-gp was
identi¢ed as an ATP-dependent transporter which exports a
wide variety of unmodi¢ed hydrophobic substrates out of the
cell including vinca alkaloids, colchicine, antibiotics and an-
thracyclines [2^5]. This protein is a 1280 amino acid integral
membrane glycoprotein (150^180 kDa) with two homologous
halves connected by a linker region. Hydropathy plots de-
duced from the amino acid sequence indicate that each of
these two regions contains six transmembrane domains and
a consensus sequence for an ATP binding domain [4,5]. P-gp
was found to be expressed in a variety of normal tissues such
as kidney, intestines, liver and at high levels in the endothelial
cells of brain capillaries [6,7]. In humans, there are two P-gp
encoded by distinct MDR genes, MDR1 which confers multi-
drug resistance, and MDR2 (also referred to as MDR3) which
is not involved in cytotoxic drug transport [4]. Rodents have
two homologues of MDR1, mdr1a and mdr1b, and one ho-
mologue of MDR2, mdr2 [4].
More recently, a high ATP-dependent transport activity for
organic anions was reported in the canalicular membrane of
hepatocytes [8,9]. This activity was identi¢ed as the canalicu-
lar multispeci¢c organic anion transporter (cMOAT) and has
been suggested to be involved in the detoxi¢cation of heavy
metals. This 190 kDa transporter, also known as Mrp2, has a
sequence homology of 49% with the human multidrug resist-
ance-associated protein (Mrp1). Studies have shown that
cMOAT is a pump which may contribute to drug resistance
by transporting a wide range of glutathione, glucuronate and
sulfate conjugates out of the cells by an ATP-dependent mech-
anism [10]. This protein is mainly expressed in the canalicular
membrane of hepatocytes but is also found in renal brush
border membranes (BBM), intestines and several multidrug-
resistant cell lines selected for cisplatin resistance [9,11,12].
Many in vitro studies have evaluated the e¡ects of dexame-
thasone on P-gp expression. However, contradictory results
were obtained [13^16] suggesting that the e¡ects of dexame-
thasone on P-gp could be related to the type of cell line used.
More recently, in vivo administration of dexamethasone was
shown to reduce P-gp expression in liver from female rats
while its expression was increased in male rats [17]. In contrast
to P-gp, nothing is known of the e¡ects of dexamethasone on
cMOAT expression. In the present study, expression of these
two members of the ATP binding cassette (ABC) family of
transport proteins (P-gp and cMOAT) was evaluated in male
rat tissues after dexamethasone treatment. Both protein levels
were evaluated by Western blot analysis using two monoclo-
nal antibodies (mAbs) for P-gp, C219 and MDR Ab-2, and a
polyclonal antibody (pAb) directed against a portion of the C-
terminal sequence of cMOAT. Both protein levels were modu-
lated in speci¢c tissues. Since dexamethasone is widely used in
chemotherapy and in multicombination therapy, the modula-
tion of P-gp and cMOAT expression in normal tissues may be
relevant to treatment e⁄cacy and to side e¡ects of the drug.
2. Materials and methods
2.1. Chemicals
Dexamethasone was purchased from Sigma-Aldrich (St. Louis,
MO). A Mini-Protean II apparatus for electrophoresis and electro-
phoresis reagents were from Bio-Rad (Mississauga, Ont.). Polyvinyli-
dene di£uoride (PVDF) membranes and a Milliblot-Graphite electro-
blotter I were from Millipore (Mississauga, Ont.). mAb C219, directed
against P-gp, was from ID Labs (London, Ont.). MDR Ab-2, which is
a mAb speci¢cally directed against human MDR1, was purchased
from Neo Markers (Fremont, CA). Anti-mouse and anti-rabbit IgG
horseradish peroxidase-linked whole antibodies were from Santa Cruz
Biotechnology (Santa Cruz, CA) while enhanced chemiluminescence
(ECL) reagents were purchased from Amersham (Oakville, Ont.).
[125I]Iodoaryl azidoprazosin (IAAP) was purchased from DuPont-
New England Nuclear (Markham, Ont.). All other reagents were
from Sigma Chemical (Oakville, Ont.).
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2.2. Dexamethasone treatments
Male Sprague-Dawley (Charles River) rats weighing 300^350 g were
treated by gavage with dexamethasone (1 mg kg31 day31) in corn oil.
The control rats received only corn oil. Rats were treated with dexa-
methasone or corn oil for 1, 2, 3 or 4 days and killed 24 h after the
last administration. The e¡ect of interruption of dexamethasone ad-
ministration was studied by treating rats daily with dexamethasone
for 4 days and killing them 1, 3 or 6 days after cessation of treatment.
For all treatments, each group of animals was made up of three rats.
2.3. Isolation of tissue crude membrane fractions and renal BBM
Crude membrane fractions were prepared from liver, lung, testis,
heart, muscle, spleen, intestine and stomach from control and treated
rats. The tissues obtained from individual animals of each group were
pooled and homogenized in a bu¡er containing 250 mM sucrose and
10 mM HEPES-Tris (pH 7.4), with a Polytron tissue homogenizer
(Brinkman Instruments, Rexdale, Ont.), and the homogenates were
centrifuged at 3000Ug for 10 min. The supernatants were then cen-
trifuged at 33 000Ug for 30 min, and the pellets containing the crude
membrane fractions were resuspended in 50 mM mannitol, 20 mM
HEPES-Tris, pH 7.5, and stored at 380‡C. Renal BBM from control
and treated rats were prepared by MgCl2 precipitation [18]. Puri¢ed
BBM were resuspended in 300 mM mannitol, 20 mM HEPES-Tris,
pH 7.5, and stored at 380‡C. Protein concentration was determined
with the Bradford assay [19].
2.4. Detection of P-gp and cMOAT
Proteins (40 Wg) from various tissues were separated by SDS-PAGE
on a 6.25% acrylamide gel according to the method of Laemmli [20].
P-gp was detected by Western blot analysis using mAbs C219 and
MDR Ab-2 (1:1000) as described previously [7]. A horseradish per-
oxidase-conjugated anti-mouse IgG was used as secondary antibody
and P-gp was revealed with ECL reagents according to the manufac-
turer’s instructions. cMOAT was also detected by Western blot anal-
ysis using the pAb developed against the C-terminal portion of this
transporter. A horseradish peroxidase-conjugated anti-rabbit IgG and
ECL reagents were used to reveal cMOAT.
2.5. Enzyme assays
Alkaline phosphatase and leucine aminopeptidase were measured
spectrophotometrically at 410 nm by standard methods as previously
used [21]. Q-Glutamyltranspeptidase activity was assayed at 410 nm
with Q-glutamyl-p-nitroanilide as a substrate as described previously
[7].
2.6. Immunization and antibody puri¢cation
The peptide EAGIENVNHTEL, corresponding to a C-terminal
portion of cMOAT, was synthesized using MAPS chemistry and
was obtained from Service de SeŁquence de Peptides de l’Est du
QueŁbec (Centre Hospitalier de l’UniversiteŁ Laval, QueŁbec, Que.).
Rabbit immunization and antibody puri¢cation were performed as
previously described [22].
2.7. Densitometric and statistical analysis
The intensity of the bands obtained from Western blot analysis and
from the photolabeling experiments was estimated with a Personal
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Fig. 1. Immunodetection of P-gp in tissues after dexamethasone treatment. Rats were treated with a daily dose (1 mg kg31 day31) of dexame-
thasone for 4 days. A: Protein samples (40 Wg) from kidney (BBM), and from crude membranes of liver, lung, muscle, heart, testis, stomach,
spleen and intestine were isolated from control (C) and treated (T) rats and were resolved by SDS-PAGE. Immunoblots were performed with
mAb C219, as described in Section 2. B: Quanti¢cation of P-gp expression in normal tissues after dexamethasone treatment. Immunoreactive
protein bands corresponding to P-gp were evaluated by laser densitometry. P-gp levels are expressed as a percentage of the total amount of im-
munoreactive protein present in tissue fractions isolated from control rats. Values represent means þ S.E.M. for at least three independent ex-
periments.
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densitometer SI (Molecular Dynamics, Sunnyvale, CA). Molecular
mass determination was performed with the following standards: my-
osin (200 kDa), L-galactoside (116 kDa), phosphorylase b (97 kDa),
bovine serum albumin (66 kDa), and ovalbumin (43 kDa). Statistical
analyses were performed using Student’s paired t-test in the Excel
program (Microsoft Excel 4.0) on a Macintosh computer. P6 0.05
was considered signi¢cant.
3. Results
3.1. E¡ect of dexamethasone treatment on P-gp expression in
rat tissues
Western blot analysis using mAb C219, which recognized
all P-gp isoforms [3], was used to evaluate P-gp expression in
tissues from rats treated with dexamethasone (1 mg kg31
day31) for 4 days (Fig. 1). In treated rats, an increase in the
level of P-gp was observed in liver and lung. In contrast, P-gp
expression was decreased in kidney while it was unchanged in
testis, heart, muscle, spleen, intestine and stomach. The mod-
ulation of P-gp expression was evaluated by laser densitome-
try, and levels of P-gp were expressed as a percentage of the
corresponding control group (Fig. 1B). In liver and lung, the
level of P-gp detected was increased 4.8- and 1.9-fold com-
pared to control rats whereas in renal BBM it was reduced
40%. Many gastrointestinal side e¡ects are associated with
dexamethasone administration, and this may explain the var-
iations in P-gp levels in intestine and stomach observed during
drug treatments. To determine whether the decrease in P-gp
expression may be related to a generalized atrophy, the weight
of tissues from control and treated rats was measured (data
not shown). The weight of tissues from treated rats was very
similar to that of control rats, except for spleen where it was
reduced 50% by dexamethasone.
In order to determine which isoform was modulated by
dexamethasone in Fig. 1, Western blot analysis using a
mAb directed speci¢cally against human MDR1 that does
not recognize MDR3 (mAb MDR Ab-2) was also performed
(Fig. 2). In treated rats, P-gp level was increased 140% in lung
whereas it was decreased 40% in renal BBM (Fig. 2B). These
results are very similar to the modulation of P-gp expression
evaluated using mAb C219. In contrast with the results ob-
tained with C219 in liver, P-gp level detected in this tissue
using mAb MDR Ab-2 was weak and very similar in control
and treated rats. These results suggest that dexamethasone
modulation involved mdr1 isoforms in lung and renal BBM
whereas it involved mdr2 in liver. In addition, dexamethasone
reduced by 40% the photolabeling of P-gp by IAAP in renal
BBM whereas in liver no labeled P-gp was detected (results
not shown). Since IAAP labels mdr1 and not mdr2 [23], the
photolabeling experiments con¢rmed the results obtained with
mAb MDR Ab-2. However, we cannot rule out the possibility
that dexamethasone could induce the sister of P-gp (spgp)
since this novel putative canalicular ABC transporter of 160
kDa has two amino acid sequences (VQEALN and
VQTALD) that are similar to the epitopes recognized by
mAbC219 [24]. This spgp should be detected by mAb C219
but not by mAb MDR1 Ab-2 since the epitopes recognized by
this antibody are not conserved. This protein contains an
additional 40 amino acids (about 5 kDa) compared to mdr
isoforms. Thus, the di¡erence in the molecular weight between
mdr isoforms and spgp should be detected with mAb C219 by
Western blots. However, no band with a higher molecular
weight than mdr isoforms and no doublet were detected sug-
gesting that this spgp of 160 kDa was not induced by dexa-
methasone. In addition, Western blots using mAb C219 de-
tected only one band in liver with an apparent molecular
weight of 145 kDa, similar to the mdr1 isoforms detected
with mAb Ab-2, suggesting once again that mAb C219 rec-
ognizes mainly mdr isoforms in these crude membranes.
Liver, lung and renal BBM were also isolated from rats
treated daily with dexamethasone (1 mg kg31 day31) for 1,
2, 3, or 4 days and at 1, 3, and 6 days after the end of 4 days
treatment. Modulation of P-gp was followed by Western blot
analysis using mAb C219 (Fig. 3A). The band corresponding
to P-gp was analyzed by laser densitometry and the data were
expressed as percentage of the P-gp expression in control rats
(Fig. 3B). In liver and lung, P-gp expression was rapidly in-
creased and reached a maximum after 2 days treatment with
dexamethasone. In renal BBM, P-gp expression decreased
after 2 days of dexamethasone administration. In these three
tissues, the level of P-gp expression returned to control values
after the interruption of dexamethasone treatment.
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Fig. 2. P-gp detection by Western blots using mAb MDR Ab-2.
Rats were treated daily with dexamethasone (1 mg kg31) for 4 days.
They were killed 24 h after the last gavage. Liver, lung and renal
BBM were isolated from control (C) and treated (T) rats. A: Pro-
tein samples (40 Wg) were resolved by SDS-PAGE. Immunoblots
were performed with mAb MDR Ab-2 (1:1000), as described Sec-
tion 2. B: Quanti¢cation of P-gp detection using mAb MDR Ab-2
in normal tissues after dexamethasone treatment. Immunoreactive
protein bands corresponding to P-gp were evaluated by laser densi-
tometry. P-gp levels are expressed as a percentage of the total
amount of immunoreactive protein present in tissue fractions iso-
lated from control rats. Values represent means þ S.E.M. for at least
three independent experiments.
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3.2. E¡ect of dexamethasone treatment on cMOAT expression
The expression of cMOAT was also evaluated in liver and
kidney by Western blot using a polyclonal antibody that we
developed against the C-terminal portion of cMOAT. This
transporter was detected as a 170^190 kDa protein depending
on the acrylamide concentration of the gel. The level of
cMOAT was higher in liver than in renal BBM from control
rats (Fig. 4). cMOAT expression was evaluated in these two
tissues from rats treated daily with dexamethasone for 1, 2, 3,
and 4 days and from rats at 1, 3 and 6 days after the end of
the treatment. cMOAT levels were rapidly increased in both
tissues by dexamethasone. A strong band of lower molecular
weight was also detected in liver, whereas in kidney it was
very faint. This protein does not seem to be related to a
degradation product since its detection in both tissues does
not correlate with variations in cMOAT levels caused by
dexamethasone. Our results suggest that this pAb directed
against cMOAT also detects unrelated proteins of lower mo-
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Fig. 3. Immunodetection of P-gp in normal tissues during treatment with dexamethasone. Rats were treated with a daily dose (1 mg kg31
day31) of dexamethasone for 1, 2, 3, and 4 days and killed 24 h after each gavage. Membranes from liver, lung and kidney (BBM) were iso-
lated from these rats as well as from rats which were treated daily with dexamethasone for 4 days and than killed at 1 (R1), 3 (R3) and 6 (R6)
days after cessation of treatment. A: Protein samples (40 Wg) from liver, lung and kidney isolated from control (C) and treated (T) rats were
resolved by SDS-PAGE. Immunoblots were performed with mAb C219, as described in Section 2. B: Quanti¢cation of P-gp expression in liver,
lung and kidney (BBM) after dexamethasone treatment. Immunoreactive protein bands corresponding to P-gp were evaluated by laser densi-
tometry. P-gp levels are expressed as a percentage of the total amount of immunoreactive protein present in tissue fractions isolated from con-
trol rats. Arrows indicate the interruption of the treatment. Values represent means þ S.D. obtained from two independent experiments.
Table 1
E¡ect of dexamethasone on membrane markers in renal BBM, liver and lung
Tissue Alkaline phosphatase
(nmol min31 mg31)
Leucine aminopeptidase
(nmol min31 mg31)
Q-Glutamyltranspetidase
(nmol min31 mg31)
Control Treated Control Treated Control Treated
Renal BBM 3340 þ 630 2200 þ 340* 297 þ 31 247 þ 24 8660 þ 1130 8470 þ 1210
Liver 5.9 þ 0.5 5.0 þ 0.4 20 þ 2 15 þ 2 BD BD
Lung 130 þ 21 96 þ 12 27 þ 1 29 þ 4 22 þ 1 29 þ 7
Alkaline phosphatase, leucine aminopeptidase and Q-glutamyltranspeptidase activities were measured in various samples isolated from control and
treated rats. Values represent means þ S.E.M. obtained from at least three di¡erent treatments.
*P6 0.05; BD = below detectable levels.
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lecular weight. The results obtained for cMOAT were ana-
lyzed by laser densitometry and the data were expressed as
the percentage of cMOAT expression in tissues from control
animals (Fig. 4B). The cMOAT levels increased approxi-
mately 2-fold during the ¢rst 3 days of dexamethasone admin-
istration, decreased the following day and returned to control
values after cessation of the treatment. We have also veri¢ed
whether this antibody could cross-react with other MRP fam-
ily members. The C-terminal portion of MRPs and cMOATb
is not very well conserved suggesting that this antibody does
not cross-react with other MRPs. For example, only one of
these 12 amino acids is identical between Mrp1 and Mrp2.
3.3. E¡ect of dexamethasone treatment on membrane enzymes
The activity of membrane marker enzymes was also eval-
uated in various samples isolated from control and treated
rats (Table 1). In renal BBM, the activity of leucine amino-
peptidase and Q-glutamyltranspeptidase were similar in control
and dexamethasone-treated rats. However, the speci¢c activity
of alkaline phosphatase decreased 35% in renal BBM after
4 days of drug treatment as well as in intestine (data not
shown). The activity of the three enzymes was much lower
in crude membranes from other tissues than in renal BBM.
In liver membranes Q-glutamyltranspeptidase was undetectable
while the two other enzyme activities were similar in control
and treated rats. The enzyme activities measured in lung were
also una¡ected by the drug. These results suggest that the
e¡ects of dexamethasone on P-gp and cMOAT in liver, lung
and kidney are speci¢c and not related to general tissue deg-
radation.
4. Discussion
The results reported here show that in vivo administration
of dexamethasone modulates P-gp and cMOAT expression.
An increase in P-gp levels following dexamethasone adminis-
tration was detected in liver and lung. This increase was rapid
since it was observed after only 1 day of treatment. For ex-
ample, subcutaneous injections of cyclosporin A (10 mg kg31
day31) are required for 4 or 5 days to induce P-gp expression
by 50^100% in various tissues (liver, kidney, intestine, lung,
heart and stomach) [7] whereas 1 day of dexamethasone treat-
ment increased P-gp expression more than 2.5-fold in liver
and lung. This increase of P-gp levels in liver by dexametha-
sone contrasts with previous in vitro studies that have shown
an early and conspicuous increase of P-gp mRNA levels in
cultured rat hepatocytes while dexamethasone-treated cells re-
pressed expression of the mdr1b gene [13] and delayed increase
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Fig. 4. Immunodetection of cMOAT in liver and in kidney during treatment with dexamethasone. Rats were treated with a daily dose (1 mg
kg31 day31) of dexamethasone for 1, 2, 3, and 4 days and killed 24 h after the last gavage. Membranes from liver and kidney (BBM) were iso-
lated from these rats as well as from rats which were treated daily with dexamethasone for 4 days and then killed at 1 (R1), 3 (R3) and 6 (R6)
days after cessation of treatment. A: Protein samples (40 Wg) from crude membranes of liver and kidney (BBM) isolated from control (C) and
treated (T) rats were resolved by SDS-PAGE. Immunoblots were performed with a pAb directed against cMOAT, as described in Section 2. B:
Quanti¢cation of cMOAT expression in liver and in renal BBM after dexamethasone treatment. Immunoreactive protein bands corresponding
to cMOAT were evaluated by laser densitometry. CMOAT levels are expressed as a percentage of the total amount of immunoreactive protein
present in tissue fractions isolated from control rats. Arrows indicate the interruption of the treatment. Values represent means þ S.D. obtained
from two independent experiments.
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of mdr mRNA [15]. However, dexamethasone has been shown
to increase the mdr1a and mdr1b proteins in a mouse hepa-
toma cell line [14] and mdr1b levels in the rat hepatoma cell
line H35 [16]. MDR1 mRNA levels were also reported to be
elevated in a dexamethasone-treated human hepatoma cell
line but not in a non-hepatoma cell line suggesting that the
hormonal regulation of mdr gene expression is gene and cell
type speci¢c [14]. A more recent study reported that admin-
istration of dexamethasone to male rats caused a ¢ve-fold
increase in P-gp expression and a three-fold increase in
mdr2 mRNA [17]. In contrast to these results, administration
of dexamethasone to female rats decreased P-gp expression
and mdr2 mRNA by 60% and 30%, respectively, suggesting
that the gender response to the drug could result from e¡ects
on a hormonal regulatory pathway. These measurements were
performed after 3^4 days of intraperitoneal administration of
dexamethasone at 80 mg kg31 day31. In the present study,
both Western blots and photoa⁄nity labeling experiments
strongly suggest that a much lower dose of dexamethasone
(1 mg kg31 day31) was su⁄cient to induce a 2.7-fold increase
in mdr2 expression in liver after only 1 day of treatment. We
have to mention that we cannot rule out the possibility that
dexamethasone may induce spgp [24]. However, Western blot
analysis performed in the present study strongly suggests that
mdr2 is modulated by dexamethasone rather than spgp. This
dose corresponds to the concentration used in the vincristine-
adriamycin-dexamethasone regimen (40 mg day31) as well as
to the initial doses (10^100 mg) for neurologic syndromes
[25,26]. Since various liver functions have been demonstrated
to be strongly modulated by corticosteroid hormones and P-
gp expression could be regulated by a hormonal regulatory
pathway [17], the reported variation in the e¡ect of dexame-
thasone on P-gp expression may be caused by di¡erences be-
tween the in vivo and in vitro responses to the drug.
In the present study, lung was the only tissue other than
liver where P-gp expression was increased by dexamethasone.
P-gp was previously detected in luminal membranes of the
vascular endothelium isolated from lung [27] and its presence
has also been reported in bronchial cells [28]. In this tissue,
glucocorticoids have been shown to increase the accumulation
of surfactant apoprotein in adult rat lung compartments after
dexamethasone treatments [29]. The increase of P-gp levels in
lung suggest that it may be involved in the regulation of the
lipid and protein components of surfactants which are hydro-
phobic molecules. Furthermore dexamethasone, which is com-
monly used for anti-in£ammatory therapy in asthma and in
interstitial lung disease, a¡ects various lung processes [30,31].
It was suggested that dexamethasone inhibition of lung epi-
thelial cell apoptosis induced by interferon-Q and Fas may be
one mechanism by which it suppresses the in£ammatory re-
sponse [32]. In other cells, the anti-in£ammatory activity of
dexamethasone was associated with inhibition of cytokine-
stimulated collagenase and stromelysin synthesis [33]. Other
matrix metalloproteases have also been reported to be in-
volved in this anti-in£ammatory process of dexamethasone
[34,35]. It is unclear to what extent any of these processes
a¡ected by dexamethasone is associated with the modulation
of P-gp expression.
P-gp expression in many tissues was una¡ected by dexame-
thasone (testis, heart, muscle, spleen, intestine and stomach).
However, a decrease in P-gp levels following dexamethasone
treatment was detected in renal BBM. Although dexametha-
sone is a potent corticosteroid the mechanism that may ex-
plain the decrease in P-gp levels detected in speci¢c tissues
remains unknown. The anti-in£ammatory, immunosuppres-
sant, anti-neoplastic and anti-emetic properties of this drug
suggest that it has many targets. In renal BBM, we have
seen a decrease in alkaline phosphatase activity. Alterations
in the activity of this enzyme by dexamethasone were also
found in intestinal BBM [36]. These results suggest that dexa-
methasone does not cause a general degradation of the renal
BBM since two other membrane markers (aminopeptidase M
and Q-glutamyltranspeptidase) were una¡ected by the drug.
In contrast to the e¡ects of dexamethasone on P-gp activity
and expression, the e¡ect of dexamethasone on cMOAT is
totally unknown. Using Western blotting analysis, we eval-
uated the e¡ect of the drug on the expression of this trans-
porter. Surprisingly, a rapid increase in cMOAT levels was
detected in liver and renal BBM. The mechanisms involved
in this modulation of cMOAT by dexamethasone remain un-
clear. Physiologically important substrates for this transporter
include glutathione S-conjugates such as leukotriene C4, bili-
rubin glucuronides and glutathione disul¢de [10], which may
be a¡ected by dexamethasone. In fact, dexamethasone was
shown to bind to a subclass of glutathione S-transferases in
rat liver [37] and to decrease bilirubin levels in patients with
metastatic colorectal cancer [38]. The increased cMOAT levels
could thus be related to variations in the content of its sub-
strates. In addition, our results suggest that the cMOAT re-
sponse to dexamethasone takes place in two steps. One pos-
sibility, as often seen with steroid hormones, could involve a
primary response which rapidly induces cMOAT expression
and a secondary response which reduces its expression even
before the end of the treatment.
In conclusion, there was a rapid modulation of P-gp and
cMOAT expression in normal tissues which was reversible.
Since dexamethasone is widely administered for di¡erent con-
ditions, the determination of the molecular mechanisms in-
volved in the modulation of these two important ABC trans-
porters is crucial for future clinical trials using this drug.
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